All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
On Sunday, 2 June, 2019, during the annual American Society of Clinical Oncology (ASCO) meeting in Chicago, US, our Steering Committee member, Maria-Victoria Mateos from University of Salamanca, Salamanca, ES, presented data from the COLUMBA trial (NCT03277105).1
COLUMBA is a phase III trial designed to show that the administration of daratumumab subcutaneously (SC) is non-inferior to the currently used, intravenous (IV) method, for the treatment of relapsed/refractory multiple myeloma (RRMM).
The first IV administration of daratumumab currently takes, on average, 7.0 hours, followed by 4.3 hours and 3.4 hours for the second and third doses respectively. Co-formulating daratumumab with recombinant human hyaluronidase PH20 (rHuPH20), increases the permeability of SC tissue, creating a SC option (dara-SC). Prior studies (Ib PAVO study, NCT02519452) have shown SC daratumumab at 1,800mg increases efficacy and pharmacokinetics (PK), and lowers the rate of infusion related reactions (IRRs) when compared to intravenous daratumumab (dara-IV).2
Data given as dara-IV versus dara-SC unless otherwise stated
Table 1: Median duration of infusion per administration, by method of administration
Dara, daratumumab; IV, intravenous; SC, subcutaneous |
|
|
Median duration of infusion (minutes) |
---|---|
First |
|
Dara-IV |
421 (7.0 hours) |
Dara-SC |
5 |
Second |
|
Dara-IV |
255 (4.3 hours) |
Dara-SC |
5 |
Subsequent |
|
Dara-IV |
205 (3.4 hours) |
Dara-SC |
5 |
Table 2: Treatment-emergent AEs (TEAEs) grade ≥3 (hematologic TEAEs occurring in ≥5% of patients, and non-hematologic TEAEs in ≥2% of patients)
|
Dara-IV (n = 258) |
Dara-SC (n = 260) |
---|---|---|
Hematologic (%) |
|
|
Anemia |
14% |
13% |
Thrombocytopenia |
14% |
14% |
Neutropenia |
8% |
13% |
Lymphopenia |
6% |
5% |
Non-hematologic (%) |
|
|
Back-pain |
3% |
2% |
Hypertension |
6% |
3% |
Dara, daratumumab; IV, intravenous; SC, subcutaneous |
Table 3: Response rates by method of administration of daratumumab
CR, complete response; Dara, daratumumab; IV, intravenous; ORR, overall response rate; PR, partial response; SC, subcutaneous; VGPR, very good partial response | ||
|
Dara-IV |
Dara-SC |
---|---|---|
ORR |
37.1% |
41.1% |
≥CR |
2.7% |
1.9% |
≥VGPR |
17.0% |
19.0% |
PR |
20.1% |
22.1% |
Median PFS and OS was similar between groups, with the data shown in Table 4.
Table 4: Median PFS and OS data in the ITT population
Dara, daratumumab; HR, hazard ratio; IV, intravenous; PFS, progression free survival; OS, overall survival; SC, subcutaneous | ||
|
Median PFS |
6-month OS rate |
---|---|---|
Dara-IV |
6.1 months (4.7–8.3) |
83% (77.6–87.2) |
Dara-SC |
5.6 months (4.7–7.6) |
87.5% (82.7–91.0) |
HR, 95% CI |
0.99 (0.78–1.26) |
0.90 (0.59–1.35) |
P value |
0.9258 |
0.6032 |
Maria-Victoria Mateos, and co-authors from the study, concluded that dara-SC is non-inferior to dara-IV as the study met both co-primary endpoints. The safety profile of both is comparable, with dara-SC being associated with a lower rate of IRRs. Significantly, patients reported an improved experience with dara-SC, based on the shorter administration time of 5 minutes, compared to hours for dara-IV.
This study supports the use of flat-dose 1,800mg dara-SC in RRMM patients having received ≥3 prior lines of therapy.
UPDATE: The results of the study were published in Lancet Haematology in March 2020 and can be accessed here
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox